Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)
China
· Delayed Price · Currency is CNY 7.83
-0.14 (-1.76%)
May 30, 2025, 1:45 PM CST
SHA:600223 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 3,929 | 3,944 | 4,511 | 12,659 | 12,201 | 13,423 | Upgrade
|
| Other Revenue | 38.9 | 38.9 | 67.66 | 292.87 | 161.85 | 192.08 | Upgrade
|
| Revenue | 3,968 | 3,983 | 4,579 | 12,951 | 12,363 | 13,615 | Upgrade
|
| Revenue Growth (YoY) | -5.46% | -13.02% | -64.65% | 4.76% | -9.20% | 32.33% | Upgrade
|
| Cost of Revenue | 1,880 | 1,891 | 2,457 | 10,025 | 9,384 | 10,856 | Upgrade
|
| Gross Profit | 2,088 | 2,091 | 2,121 | 2,926 | 2,980 | 2,760 | Upgrade
|
| Selling, General & Admin | 1,636 | 1,644 | 1,668 | 1,661 | 1,628 | 1,172 | Upgrade
|
| Research & Development | 175.67 | 166.77 | 153.36 | 133.92 | 118.75 | 77.17 | Upgrade
|
| Other Operating Expenses | 40.61 | 40.15 | 36.42 | 539.39 | 585.63 | 747.88 | Upgrade
|
| Operating Expenses | 1,882 | 1,877 | 1,894 | 2,350 | 2,343 | 1,994 | Upgrade
|
| Operating Income | 205.93 | 214.71 | 227.71 | 575.66 | 636.91 | 765.96 | Upgrade
|
| Interest Expense | -19.2 | -22.12 | -94.75 | -400.97 | -112.32 | -91.2 | Upgrade
|
| Interest & Investment Income | 112.29 | 115.8 | 259.29 | 163.61 | 239.56 | 255.8 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.85 | 1.85 | 0.32 | 12.59 | -1.14 | -2.44 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.72 | -1.7 | -8 | -62.17 | -139.2 | -97.69 | Upgrade
|
| EBT Excluding Unusual Items | 299.15 | 308.55 | 384.56 | 288.73 | 623.82 | 830.43 | Upgrade
|
| Impairment of Goodwill | - | - | -1.85 | -4.74 | -3.98 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.11 | 0.42 | -1.12 | 0.44 | -0.04 | 0.09 | Upgrade
|
| Asset Writedown | 0.74 | - | - | - | - | -0.93 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -6.4 | Upgrade
|
| Other Unusual Items | 35.53 | 37.33 | 31.37 | -23.37 | 23.93 | 30.32 | Upgrade
|
| Pretax Income | 335.32 | 346.29 | 412.96 | 261.06 | 643.73 | 853.5 | Upgrade
|
| Income Tax Expense | 48.87 | 49.85 | 46.82 | 195.96 | 249.93 | 214.61 | Upgrade
|
| Earnings From Continuing Operations | 286.45 | 296.44 | 366.14 | 65.1 | 393.8 | 638.89 | Upgrade
|
| Minority Interest in Earnings | -51.25 | -52.92 | -62.75 | -19.64 | -31.9 | -0.22 | Upgrade
|
| Net Income | 235.2 | 243.53 | 303.39 | 45.46 | 361.9 | 638.67 | Upgrade
|
| Net Income to Common | 235.2 | 243.53 | 303.39 | 45.46 | 361.9 | 638.67 | Upgrade
|
| Net Income Growth | 0.91% | -19.73% | 567.44% | -87.44% | -43.34% | 85.39% | Upgrade
|
| Shares Outstanding (Basic) | 1,022 | 1,015 | 1,011 | 1,136 | 1,005 | 998 | Upgrade
|
| Shares Outstanding (Diluted) | 1,022 | 1,015 | 1,011 | 1,136 | 1,034 | 1,014 | Upgrade
|
| Shares Change (YoY) | 1.36% | 0.34% | -11.01% | 9.90% | 2.00% | 0.05% | Upgrade
|
| EPS (Basic) | 0.23 | 0.24 | 0.30 | 0.04 | 0.36 | 0.64 | Upgrade
|
| EPS (Diluted) | 0.23 | 0.24 | 0.30 | 0.04 | 0.35 | 0.63 | Upgrade
|
| EPS Growth | -0.45% | -20.00% | 650.00% | -88.57% | -44.44% | 85.29% | Upgrade
|
| Free Cash Flow | -73.71 | 71.44 | 262.79 | 831.98 | 6,567 | 4,291 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | 0.07 | 0.26 | 0.73 | 6.35 | 4.23 | Upgrade
|
| Dividend Per Share | 0.110 | 0.110 | 0.100 | 0.110 | 0.110 | 0.200 | Upgrade
|
| Dividend Growth | 10.00% | 10.00% | -9.09% | - | -45.00% | 81.82% | Upgrade
|
| Gross Margin | 52.62% | 52.51% | 46.33% | 22.59% | 24.10% | 20.27% | Upgrade
|
| Operating Margin | 5.19% | 5.39% | 4.97% | 4.45% | 5.15% | 5.63% | Upgrade
|
| Profit Margin | 5.93% | 6.12% | 6.63% | 0.35% | 2.93% | 4.69% | Upgrade
|
| Free Cash Flow Margin | -1.86% | 1.79% | 5.74% | 6.42% | 53.12% | 31.51% | Upgrade
|
| EBITDA | 289.05 | 308.37 | 363.55 | 692.15 | 729.53 | 851.95 | Upgrade
|
| EBITDA Margin | 7.28% | 7.74% | 7.94% | 5.34% | 5.90% | 6.26% | Upgrade
|
| D&A For EBITDA | 83.12 | 93.66 | 135.84 | 116.49 | 92.62 | 85.99 | Upgrade
|
| EBIT | 205.93 | 214.71 | 227.71 | 575.66 | 636.91 | 765.96 | Upgrade
|
| EBIT Margin | 5.19% | 5.39% | 4.97% | 4.45% | 5.15% | 5.63% | Upgrade
|
| Effective Tax Rate | 14.57% | 14.40% | 11.34% | 75.06% | 38.83% | 25.14% | Upgrade
|
| Revenue as Reported | 3,968 | 3,983 | 4,579 | 12,951 | 12,363 | 13,615 | Upgrade
|
| Advertising Expenses | - | 811.13 | 784.1 | 705.36 | 630.15 | 388.03 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.